Trivalent MDCK cell culture-derived influenza vaccine Optaflu® (Novartis Vaccines)

Expert Review of Vaccines

Volumn 8, Issue 6, 2009, Pages 679-688

  Doroshenko, Alexander ^b   Halperin, Scott A ^a,b  

^a IWK HEALTH CENTRE   (Canada)

^b DALHOUSIE UNIVERSITY   (Canada)

Author keywords

Influenza pandemic; Influenza vaccine; MDCK cell culture

Indexed keywords

INFLUENZA VACCINE;

BIOMEDICAL ENGINEERING; CELL STRAIN; CLINICAL TRIAL; DEVELOPED COUNTRY; DEVELOPING COUNTRY; DRUG SAFETY; HUMAN; IMMUNOGENICITY; INFLUENZA; INFLUENZA VACCINATION; MORBIDITY; MORTALITY; PRIORITY JOURNAL; REVIEW; UNSPECIFIED SIDE EFFECT;

ANIMALS; CELL LINE; DOGS; HUMANS; INFLUENZA VACCINES; ORTHOMYXOVIRIDAE;

EID: 67449102487     PISSN: 14760584     EISSN: 17448395     Source Type: Journal    
DOI: 10.1586/erv.09.31     Document Type: Review

References (31)

1. WHO. Cell culture as a substrate for the production of influenza vaccines: memorandum from a WHO meeting. Bull. World Health Organ. 73(4), 431-435 (1995).
2. Bardiya N, Bae JH. Influenza vaccines: recent advances in production technologies. Appl. Microbiol. Biotechnol. 67, 299-305 (2005). (Pubitemid 40691198)
3. CDC. Prevention and control of influenza: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm. Rep. 49(RR-3), 1-38 (2000).
4. Genzel Y, Olmer RM, Schafer B, Reichl U. Wave microcarrier cultivation of MDCK cells for influenza virus production in serum containing and serum-free media. Vaccine 24, 6074-6087 (2006). (Pubitemid 44175621)
5. Opitz L, Salaklang J, Buttner H, Reichl U, Wolff M. Lectin-affinity chromatography for downstream processing of MDCK cell culture derived human influenza A viruses. Vaccine 25, 939-947 (2007). (Pubitemid 44856117)
6. CDC. Prevention and control of influenza: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm. Rep. 53(RR-6), 1-40 (2004). Erratum: MMWR Morb. Mortal. Wkly Rep. 53(32), 743 (2004).
7. Bryan J. Race to find new vaccine production techniques in fight against influenza. Pharm J. 275(7373), 543-544 (2005). (Pubitemid 41645265)
8. Ehrlich H, Müller M, Oh HML et al. A clinical trial of a whole-virus H5N1 vaccine derived from cell culture. N. Engl. J. Med. 358, 2573-2584 (2008).
9. Palache AM, Brands R, van Scharrenburg GJM. Immunogenicity and reactogenicity of influenza subunit vaccines produced in MDCK cells or fertilized chicken eggs. J. Infect. Dis. 176(Suppl. 1), S20-S23 (1997). (Pubitemid 27315341)
10. Halperin SA, Nestruck AC, Eastwood BJ. Safety and immunogenicity of a new influenza vaccine grown in mammalian cell culture. Vaccine 16, 1331-1335 (1998). (Pubitemid 28308415)
11. Halperin SA, Smith B, Mabrouk T et al. Safety and immunogenicity of a trivalent, inactivated, mammalian cell culture-derived influenza vaccine in healthy adults, seniors, and children. Vaccine 20, 1240-1247 (2002). (Pubitemid 34135962)
12. Trusheim H, Roth B, Wilms R et al. The MDCK 33016-PF cell line is not only suitable for the production of cell-based influenza vaccine but is also an ideal substrate for influenza virus isolation. Presented at: Options for the Control of Influenza VI Conference. Toronto, ON, Canada, 17-23 June 2007.
13. Groth N, Ambrozaitis A, Bugarini R, Podda A. Consistent immunoresponse and tolerability of different lots of a new influenza subunit vaccine produced in MDCK cells. Presented at: 45th Annual Meeting of IDSA. San Diego, CA, USA, 4-7 October 2007. Abstract Poster P794.
14. Reisinger KS, Block SL, Bugarini R et al. Safety, tolerability and immunogenicity of a MDCK vaccine compared to Fluvirin: a Phase 2 study. Presented at: Options for the Control of Influenza VI Conference. Toronto, ON, Canada, 17-23 June 2007. Abstract P717.
15. Groth N, Szymczakiewicz-Multanowska A, Bugarini R et al. Non-inferiority of a new influenza subunit vaccine produced in MDCK cells compared to an egg-based conventional influenza vaccine. In: Program and Abstracts of the Tenth Annual Conference on Vaccine Research. Baltimore, MD, USA, 30 April-2 May 2007. Abstract Poster P56.
16. Groth N, Montomoli E, Gentile C, Manini I, Bugarini R, Podda A. Safety, tolerability and immunogenicity of a mammalian cell-culture-derived influenza vaccine: a sequential Phase I and Phase II clinical trial. Vaccine 27, 786-791 (2009).
17. Wright PF. Vaccine preparedness - are we ready for the next influenza pandemic? N. Engl. J. Med. 358, 2540-2543 (2008).
18. Novartis Vaccines and Diagnostics, Inc. MDCK 33016 cell line. Patent No. WO/1997/037000 (1997).
19. WHO. Influenza Fact Sheet www.who.int/mediacentre/factsheets/fs211/en/
20. WHO. Initiative for Vaccine Research. Use of cell lines for the production of influenza virus vaccines: an appraisal of technical, manufacturing and regulatory considerations. Geneva, Switzerland, 10 April 2007 www.who.int/vaccine-research/diseases/influenza/WHO-flu-cell-substrate-version3. pdf
21. Rappuoli R. Cell-culture-based vaccine production: technological options. National Academy of Engineering Publications. The Bridge 36(3), 25-30 (2006) www.nae.edu/nae/bridgecom.nsf/weblinks/mkez-6szr4l?opendocument
22. Novartis Vaccines. Flu cell culture technology: the next frontier www.novartisvaccines.com/pipeline/flu-culture.shtml
23. Flu vaccine: Recent supply shortages underscore ongoing challenges: Testimony before the Subcommittee on Health and the Subcommittee on Oversight and Investigations, Committee on Energy and Commerce, US House of Representatives. 18 November 2004 www.gao.gov/cgi-bin/getrpt?GAO-05-177T
24. Baxter announces final Phase I/II data and initiation of Phase III clinical trial for candidate pandemic H5N1 influenza vaccine (news release). Baxter International Inc., Deerfield, IL, USA, 29 March 2007 www.baxter.com/about-baxter/news-room/news-releases/2007/03-29-07-h5n1.html
25. European Medicines Agency. EPARs for authorised medicinal products for human use: Optaflu www.emea.europa.eu/humandocs/humans/epar/optaflu/optaflu.htm •• Provides a summary of indications, procedural steps for the authorization and scientific discussion on the Optaflu® vaccine.
26. International Federation of Pharmaceutical Manufacturers & Associations. R&D for avian/pandemic influenza vaccines by IFPMA Influenza Vaccine Supply International Taskforce (IVS ITF) members. IFPM, Geneva, Switzerland, 17 October 2006 www.ifpma.org/influenza/content/pdfs/table-avian- pandemic-influenza-rnd-17oct06.pdf
27. Committee for Proprietary Medicinal Products. Note for guidance on harmonisation of requirements for influenza vaccines. The European Agency for the Evaluation of Medicinal Products, London, UK, 12 March 1997 www.emea.europa.eu/pdfs/human/bwp/021496en.pdf
28. Chiron. Use of MDCK cells for manufacture of inactivated influenza virus vaccine. Presented at: VRBPAC meeting, US Food and Drug Administration, 16 November 2005. www.fda.gov/ohrms/dockets/ac/05/slides/5-4188S1-5.pdf • Concise description of the characteristics of the Madin-Darby canine kidney cell line and of the manufacturing process.
29. Center for Biologics Evaluation and Research. Characterization and qualification of cell substrates and other biological starting materials used in the production of viral vaccines for the prevention and treatment of infectious diseases. Food and Drug Administration, Rockville, MD, USA, September 2006 www.fda.gov/cber/gdlns/vaccsubstrates.pdf
30. Committee for Medicinal Products for Human Use. Summary of positive opinion for Celvapan. The European Agency for the Evaluation of Medicinal Products, London, UK, 18 December 2008 www.emea.europa.eu/pdfs/human/opinion/ celvapan-65700508en.pdf
31. Committee for Proprietary Medicinal Products. Note for guidance on clinical evaluation of new vaccines. The European Agency for the Evaluation of Medicinal Products, London, UK, 19 May 1999 www.emea.europa.eu/pdfs/human/ewp/ 046397en.pdf